Literature DB >> 15590404

In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor.

Huang Xiao Jun1, Chang Ying Jun, Zhao Xiang Yu.   

Abstract

BACKGROUND AND OBJECTIVES: Granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (G-BM) transplantation is associated with a low incidence of graft-versus-host disease (GVHD) and has been used successfully in patients with human leukocyte antigen (HLA) matched/mismatched donors. This study evaluated the function of T cells and the quantities of immunological cells of G-BM. DESIGN AND METHODS: Bone marrow was obtained from fifteen donors by aspiration. Lymphocyte proliferation ability, interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) secreted by T cells were determined using a monotetrazolium (MTT) assay and sandwich enzyme-linked immunosorbent assay (ELISA), respectively. T-cell subgroups, dendritic cell (DC) subsets, CD4(+)CD25(+) regulatory T cells and the expression of CD28/CD80/CD86 molecules on monocytes, B and T cells were analyzed using flow cytometry.
RESULTS: G-CSF treatment decreased the quantities of IFN-gamma secretion dramatically (p=0.007) and IL-4 moderately (p=0.027), leading to higher ratios of IL-4/IFN-gamma (p=0.004). We confirmed T-cell hyporesponsiveness and lower expression of CD28/CD80/CD86 on monocytes, B and T cells. The absolute values of lymphocytes, T cell subgroups, CD3+CD4-CD8- cells, CD8+CD28- cells and B cells in bone marrow grafts were similar before and after G-CSF treatment. The number of monocytes per microliter was increased 2.13-fold, while the numbers of CD4(+)CD25(+) regulatory T cells were unchanged. DC2 were preferentially increased. INTERPRETATION AND
CONCLUSIONS: Our results suggest that bone marrow T-cell hyporesponsiveness could be induced and that the increase of monocytes and DC2 and the downregulation of CD28/CD80/CD86 co-stimulatory signals were produced by in vivo use of G-CSF; this may be related to the preferential increase of monocytes and DC2 and the downregulation of CD28/CD80/CD86 co-stimulatory signals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15590404

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  28 in total

Review 1.  Advancement of human leukocyte antigen-partially matched related hematopoietic stem cell transplantation.

Authors:  Xiaodong Mo; Xiaojun Huang
Journal:  Front Med       Date:  2013-07-20       Impact factor: 4.592

Review 2.  Progress in haploidentical stem cell transplantation.

Authors:  Ulas D Bayraktar; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-09       Impact factor: 5.742

Review 3.  Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.

Authors:  F Saraceni; N Shem-Tov; A Olivieri; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

4.  Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.

Authors:  J Chen; R-X Wang; F Chen; A-N Sun; H-Y Qiu; Z-M Jin; X-W Tang; Y Han; Z-Z Fu; G-S He; M Miao; X Ma; D-P Wu
Journal:  Bone Marrow Transplant       Date:  2013-10-21       Impact factor: 5.483

Review 5.  Haploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectives.

Authors:  Lei Gao; Xi Zhang
Journal:  Stem Cell Investig       Date:  2015-10-20

Review 6.  G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept.

Authors:  U Deotare; G Al-Dawsari; S Couban; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

Review 7.  Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.

Authors:  Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

8.  Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia.

Authors:  Xiao-Jun Huang; Dai-Hong Liu; Kai-Yan Liu; Lan-Ping Xu; Yu-Hong Chen; Yu Wang; Wei Han; Huan Chen
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

9.  Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia--feasibility and safety study.

Authors:  Xiao-Jun Huang; Yu Wang; Dai-Hong Liu; Lan-Ping Xu; Huan Chen; Yu-Hong Chen; Wei Han; Hong-Xia Shi; Kai-Yan Liu
Journal:  J Clin Immunol       Date:  2008-03-18       Impact factor: 8.317

Review 10.  Current status of haploidentical stem cell transplantation for leukemia.

Authors:  Xiao-jun Huang
Journal:  J Hematol Oncol       Date:  2008-12-31       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.